COMPOSITION FOR THE NUTRITION OR DRINK OF A NON-HUMAN ANIMAL

    公开(公告)号:US20240115633A1

    公开(公告)日:2024-04-11

    申请号:US18263992

    申请日:2022-02-07

    摘要: The present invention relates to a composition for the nutrition or drink of a non-human animal comprising the combination of spirulina and Ascophyllum nodosum. It further relates to the use of this composition for improving the zootechnical performance of non-human animals, in order to reduce the emission of greenhouse gases, in particular methane, in a non-human mammal, in order to increase the digestibility of the dry matter and fibers, in particular forage and concentrates, and/or to improve the consumption index and/or the dietary efficiency and/or to promote weight gain and/or to increase the intensity of fermentation and of microbial metabolism and/or to inhibit flora protozoa and/or to reduce the degradation of proteins and/or to orient the fermentation towards the production of volatile fatty acids in a non-human mammal, in order to improve the quality of the meat and/or the growth performance and/or the well-being of a non-human animal. It also relates to the composition according to the invention, for its use for improving the intestinal health and/or the intestinal well-being and/or the immune system and/or the bone mineralization and/or the quality of the bone structure and/or as an antibacterial in non-human animals and/or to increase the intestinal villi of monogastric non-human animals and/or to modulate the inflammatory response and/or to avoid damage associated with post-weaning nutritional stress in monogastric mammals.

    COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING DEGENERATIVE MITRAL VALVE DISEASE IN A CANINE

    公开(公告)号:US20230407410A1

    公开(公告)日:2023-12-21

    申请号:US18112785

    申请日:2023-02-22

    发明人: Qinghong Li

    摘要: Methods and compositions diagnose and treat degenerative mitral valve disease in a canine. A method of diagnosing early stage degenerative mitral valve disease in a canine can include measuring a normalized relative abundance of a biomarker selected from the group consisting of Erysipelatoclostridium, Ruminococcaceae UCG014, Butyricicoccus, Faecalibacterium, and combinations thereof; and determining that the canine has early stage degenerative mitral valve disease if the Erysipelatoclostridium is from 0 to 0.5 normalized relative abundance, the Ruminococcaceae UCG014 is from 0 to 0.1 normalized relative abundance, the Butyricicoccus is from 0 to 0.1 normalized relative abundance, or the Faecalibacterium is from 0 to 0.1 normalized relative abundance.